Eva Havrdova

Eva Havrdova

UNVERIFIED PROFILE

Are you Eva Havrdova?   Register this Author

Register author
Eva Havrdova

Eva Havrdova

Publications by authors named "Eva Havrdova"

Are you Eva Havrdova?   Register this Author

100Publications

3805Reads

24Profile Views

Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.

Mult Scler 2020 Jan 21:1352458519901272. Epub 2020 Jan 21.

Department of Neurology and Center of Clinical Neuroscience, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458519901272DOI Listing
January 2020

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.

Mult Scler 2019 04 16;25(4):541-553. Epub 2017 Nov 16.

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517742739DOI Listing
April 2019

Establishing pathological cut-offs for lateral ventricular volume expansion rates.

Neuroimage Clin 2018 7;18:494-501. Epub 2018 Feb 7.

Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nicl.2018.02.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842310PMC
February 2019

Real-Life Outcome in Multiple Sclerosis in the Czech Republic.

Mult Scler Int 2019 18;2019:7290285. Epub 2019 Feb 18.

Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7290285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397999PMC
February 2019

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Mult Scler 2018 10 31;24(12):1617-1626. Epub 2017 Aug 31.

Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia/Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia/Department of Neurology, Box Hill Hospital, Monash University, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517728812DOI Listing
October 2018

Do eyes with and without optic neuritis in multiple sclerosis age equally?

Neuropsychiatr Dis Treat 2018 5;14:2281-2285. Epub 2018 Sep 5.

Center of Clinical Neuroscience, Department of Neurology, General University Hospital, 1st Faculty of Medicine, Charles University, Prague Czech Republic,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/NDT.S169638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130290PMC
September 2018

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.

Neuroimage Clin 2017 19;15:769-779. Epub 2017 Jun 19.

Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA; MR Imaging Clinical Translational Research Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nicl.2017.06.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496213PMC
June 2018

Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.

Neuroimage Clin 2018 5;17:444-451. Epub 2017 Nov 5.

Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nicl.2017.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684496PMC
June 2018

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.

J Neurol Sci 2018 05 6;388:87-93. Epub 2018 Mar 6.

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.045DOI Listing
May 2018

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Mult Scler 2018 02 20;24(2):96-120. Epub 2018 Jan 20.

Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunology (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517751049DOI Listing
February 2018

Management of multiple sclerosis patients in central European countries: current needs and potential solutions.

Ther Adv Neurol Disord 2018 22;11:1756286418759189. Epub 2018 Feb 22.

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286418759189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826096PMC
February 2018

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.

J Neuroimaging 2017 11 2;27(6):620-629. Epub 2017 May 2.

Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jon.12445DOI Listing
November 2017

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Ther Clin Risk Manag 2017 16;13:1423-1437. Epub 2017 Oct 16.

Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.

View Article

Download full-text PDF

Source
https://www.dovepress.com/understanding-the-positive-benefit
Publisher Site
http://dx.doi.org/10.2147/TCRM.S143509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652900PMC
October 2017

Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5).

Eur Neurol 2016 6;76(3-4):99-104. Epub 2016 Aug 6.

Department of Neurology and Centre of Clinical Neuroscience, First School of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000448091DOI Listing
September 2017

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.

Mult Scler 2017 Sep 25;23(10):1367-1376. Epub 2016 Nov 25.

Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458516677589DOI Listing
September 2017

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Neurology 2017 Sep 23;89(11):1107-1116. Epub 2017 Aug 23.

From the Department of Neurology and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic; NeuroRx Research (D.L.A.), Montréal; Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; MS Clinic of Central Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK; Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, University Hospital Zürich and University of Zürich, Switzerland; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; The University of British Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595278PMC
September 2017

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Neurology 2017 Sep 23;89(11):1117-1126. Epub 2017 Aug 23.

From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary University of London (G.G.), Barts and the London School of Medicine, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles University and General Hospital in Prague, Czech Republic; Neuroimmunology and Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital Zürich and University of Zürich, Switzerland; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; The University of British Columbia (A.T.), Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montréal; Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada. M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004354DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595276PMC
September 2017

"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.

Mult Scler 2017 Aug 6;23(9):1179-1187. Epub 2017 Apr 6.

Department of Neurology and Center of Clinical Neuroscience, Charles University, Prague, Czech Republic/First Faculty of Medicine, Charles University, Prague, Czech Republic/General University Hospital, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517703193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536258PMC
August 2017

Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients.

BMC Neurol 2017 Jul 28;17(1):145. Epub 2017 Jul 28.

Department of Neurology and Centre of Clinical Neuroscience First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12883-017-0915-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534044PMC
July 2017

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.

Autoimmun Rev 2017 Jun 17;16(6):658-665. Epub 2017 Apr 17.

Department of Medicine, University of Melbourne, 300 Grattan St, Melbourne 3050, Australia; Department of Neurology, Royal Melbourne Hospital, 300 Grattan St, Melbourne 3050, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2017.04.010DOI Listing
June 2017

MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.

Brain Behav 2017 03 9;7(3):e00644. Epub 2017 Feb 9.

Department of Neurology Charles University 2nd Faculty of Medicine and Motol University Hospital Prague Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/brb3.644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346526PMC
March 2017

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

Mult Scler 2017 Feb 11;23(2):242-252. Epub 2016 Jul 11.

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458516650525DOI Listing
February 2017

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.

Mult Scler 2017 01 11;23(1):51-61. Epub 2016 Jul 11.

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458516642314DOI Listing
January 2017

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.

Mult Scler Relat Disord 2017 Jan 13;11:18-24. Epub 2016 Nov 13.

Biogen, 225 Binney Street, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2016.11.005DOI Listing
January 2017

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.

Mult Scler 2016 11 16;22(13):1709-1718. Epub 2016 Feb 16.

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458516629769DOI Listing
November 2016

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Neurology 2016 Nov 12;87(19):1985-1992. Epub 2016 Oct 12.

From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA; and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted).

View Article

Download full-text PDF

Source
http://www.neurology.org/lookup/doi/10.1212/WNL.000000000000
Publisher Site
http://dx.doi.org/10.1212/WNL.0000000000003319DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109953PMC
November 2016

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Neurology 2016 Oct 2;87(14):1464-1472. Epub 2016 Sep 2.

From NeuroRx Research (D.L.A.) and Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada; Department of Biomedical Engineering (E.F.) and Mellen Center (J.A.C.), Cleveland Clinic, OH; Zagreb Medical School and University Hospital Center (V.V.B.), Croatia; Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Queen Mary University of London (G.G.), Barts and the London School of Medicine, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; Clinical Centre Kragujevac (M.S.), Clinic of Neurology, Serbia; Brigham and Women's Hospital Center for Neurologic Diseases (H.L.W.), Boston, MA; Sanofi Genzyme (S.L.L., D.H.M., M.A.P.), Cambridge, MA; and Evidence Scientific Solutions (D.R.T.), Horsham, West Sussex, UK. Dr. Panzara is currently with Wave Life Sciences, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075976PMC
October 2016

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.

J Neurol 2016 Jul 3;263(7):1287-95. Epub 2016 May 3.

Neuroscience Translational Medicine, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Fabrikstrasse 12, 4002, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-016-8128-xDOI Listing
July 2016

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

Mult Scler 2016 05 11;22(6):770-81. Epub 2015 Sep 11.

Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, USA/MR Imaging Clinical Translational Research Center, State University of New York, Buffalo, NY, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458515601903DOI Listing
May 2016

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Neurol Clin Pract 2016 Apr;6(2):102-115

Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital (TS, TK, VJ, HB), University of Melbourne, Australia; Biogen Idec Inc. (AZ, FP, SB, RH), Cambridge, MA; Department of Neurology (HW), University of Münster, Germany; Groene Hart Ziekenhuis (FV), Gouda, the Netherlands; MS Center, Department of Neuroscience, Imaging and Clinical Sciences (AL), University "G. d'Annunzio," Chieti, Italy; MS Center, Department of Neurology, First Medical Faculty (EH, DH), Charles University, Prague, Czech Republic; Center de Réadaptation Déficience Physique Chaudière-Appalache (PG), Levis; Hôpital Notre Dame (PD, AP), Montreal, Canada; Ospedali Riuniti di Salerno (G. Iuliano), Salerno, Italy; 19 Mayis University (M. Terzi), Medical Faculty, Turkey; Hospital Universitario Virgen Macarena (G. Izquierdo), Sevilla, Spain; Orbis Medical Centre (RMMH), Sittard-Geleen, the Netherlands; KTU Medical Faculty Farabi Hospital (CB), Trabzon, Turkey; Neurology Unit (EP, GG), ASUR Marche-AV3, Macerata; Nuovo Ospedale Civile S. Agostino (PS), Modena; AORN San Giuseppe Moscati (DLAS), Avellino, Italy; John Hunter Hospital (JL-S), Newcastle, Australia; Neurological Institute IRCCS Mondino (RB), Pavia, Italy; Neuro Rive-Sud (F. Grand'Maison), Hôpital Charles LeMoyne, Quebec, Canada; University of Parma (F. Granella), Italy; Department of Neurology (LK), University Hospital Basel, Switzerland; Department of Basic Medical Sciences, Neuroscience and Sense Organs (M. Trojano), University of Bari, Italy; and Department of Neurology (HB), Eastern Health, Monash University, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CPJ.0000000000000227DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828679PMC
April 2016

Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.

Mult Scler Relat Disord 2016 Mar 1;6:66-72. Epub 2016 Feb 1.

University of Colorado School of Medicine, Anschutz Medical Campus, Department of Neurology, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2016.02.001DOI Listing
March 2016

The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalus.

Neuro Endocrinol Lett 2015 Dec;36(6):564-71

1st Faculty of Medicine, Charles University in Prague, Czech Republic.

View Article

Download full-text PDF

Source
December 2015

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

J Lipid Res 2015 Oct 4;56(10):2010-8. Epub 2015 Aug 4.

Departments of Pharmaceutical Sciences, State University of New York, Buffalo, NY Neurology, State University of New York, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1194/jlr.M060970DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583090PMC
October 2015

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

N Engl J Med 2015 Oct;373(15):1418-28

From the Neurologic Clinic and Policlinic, the Departments of Medicine, Clinical Research, and Biomedicine and Biomedical Engineering, University Hospital, Basel, Switzerland (L.K.); the Department of Neurology, University of Münster, Münster, Germany (H.W.); the Department of Neurology, Medical University of Lodz, Lodz, Poland (K.S.); NeuroRx Research and Montreal Neurological Institute, McGill University - both in Montreal (D.L.A.); the Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic (E.H.); the Department of Neurology and Neurosurgery, Russian National Research Medical University, and Moscow Multiple Sclerosis Center - both in Moscow (A.B.); Cole Neurological Institute, University of Tennessee, Knoxville (M.K.); the Department of Neurology and the Neurovirology Research Laboratory, University of Utah, and the Veterans Affairs Salt Lake City Health Care System - both in Salt Lake City (J.R.); AbbVie Biotherapeutics, Redwood City, CA (S.G.); and Biogen, Cambridge, MA (M.S., K.R., G.O., J.E.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1501481
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1501481DOI Listing
October 2015

Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.

Int J MS Care 2015 Sep-Oct;17(5):236-43

Multiple Sclerosis Program, Baylor Institute for Immunology Research, Dallas, TX, USA (JTP); Medical University of Lodz, Lodz, Poland (KS); St. Josef Hospital, Ruhr University, Bochum, Germany (RG); Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA (RJF); Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic (EH); Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK (GG); and Biogen, Cambridge, MA, USA (HA, AP, MN, CH, VV, LM).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7224/1537-2073.2014-069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599361PMC
October 2015

MRI correlates of disability progression in patients with CIS over 48 months.

Neuroimage Clin 2014 28;6:312-9. Epub 2014 Sep 28.

Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA ; MR Imaging Clinical Translational Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nicl.2014.09.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215387PMC
July 2015

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.

Neurology 2015 Mar 13;84(11):1145-52. Epub 2015 Feb 13.

From the Departments of Neuroinflammation (D.H.M., C.A.M.W.-K., D.J.T., D.G.M.) and Brain Repair and Rehabilitation (T.A.Y.), NMR Research Unit, Queen Square Multiple Sclerosis Centre; University College London Institute of Neurology (D.H.M., C.A.M.W.-K., D.J.T., D.G.M., T.A.Y.), UK; Mellen Center for Multiple Sclerosis Treatment and Research (R.J.F.), Cleveland Clinic, OH; Multiple Sclerosis Program (J.T.P.), Baylor Institute for Immunology Research, Dallas, TX; St. Vincent's University Hospital (M.H.), Elm Park, Donnybrook, Dublin, Ireland; Department of Neurology (E.H.), First Faculty of Medicine, Charles University, Prague, Czech Republic; Virginia Mason Medical Center (M.K.), Seattle, WA; CircleScience (M.G.), Tytherington, UK; and Biogen Idec Incorporated (M.Y., R.Z., V.V., K.T.D.), Weston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000001360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371413PMC
March 2015

Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).

J Neuroeng Rehabil 2015 Feb 10;12:14. Epub 2015 Feb 10.

Department of Neurology and Centre of Clinical Neuroscience, Charles University in Prague, First School of Medicine and General University Hospital, Katerinska 32, Prague 1, 128 00, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12984-015-0001-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334845PMC
February 2015

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

Ther Adv Neurol Disord 2015 Jan;8(1):31-45

Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University in Prague, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1756285614563522
Publisher Site
http://dx.doi.org/10.1177/1756285614563522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286943PMC
January 2015

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment.

J Neurol Sci 2014 Dec 8;347(1-2):229-34. Epub 2014 Oct 8.

Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA; MR Imaging Clinical Translational Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022510X140065
Publisher Site
http://dx.doi.org/10.1016/j.jns.2014.10.002DOI Listing
December 2014

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.

JAMA Neurol 2014 Nov;71(11):1386-93

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio7currently with Biogen Idec, Weston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2014.1895DOI Listing
November 2014

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.

J Steroid Biochem Mol Biol 2014 Sep 17;143:424-33. Epub 2014 Jun 17.

Department of Neurology, State University of New York, Buffalo, NY, USA; Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsbmb.2014.06.007DOI Listing
September 2014

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.

J Neurol 2014 Sep 22;261(9):1735-44. Epub 2014 Jun 22.

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-014-7413-9DOI Listing
September 2014

Complement activation in patients with neuromyelitis optica.

J Neuroimmunol 2014 Sep 11;274(1-2):185-91. Epub 2014 Jul 11.

Laboratory of Clinical Immunology, Department of Biomedicine, University Hospital Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2014.07.001DOI Listing
September 2014

Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.

J Neurol Neurosurg Psychiatry 2014 Aug 27;85(8):859-64. Epub 2014 Jan 27.

Department of Neurology, State University of New York, Buffalo, New York, USA Department of Pharmaceutical Sciences, State University of New York, Buffalo, New York, USA.

View Article

Download full-text PDF

Source
http://jnnp.bmj.com/cgi/doi/10.1136/jnnp-2013-307106
Publisher Site
http://dx.doi.org/10.1136/jnnp-2013-307106DOI Listing
August 2014

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study.

J Neuroimmunol 2014 Aug 30;273(1-2):58-64. Epub 2014 Apr 30.

Department of Neurology, State University of New York, Buffalo, NY, USA; Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2014.04.012DOI Listing
August 2014

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel.

Mult Scler Relat Disord 2014 Jul 1;3(4):513-9. Epub 2014 Apr 1.

Charles University in Prague, Katerinska 30, 12808 Praha 2, Prague, Czech Republic. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2014.03.003DOI Listing
July 2014

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.

J Neurol 2014 Feb 29;261(2):316-23. Epub 2013 Dec 29.

Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-013-7196-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915085PMC
February 2014

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.

Neurology 2014 Feb 22;82(7):573-81. Epub 2014 Jan 22.

From the Danish Multiple Sclerosis Center (P.S.S.), Rigshospitalet, Copenhagen; Genmab (S.L.), Copenhagen, Denmark; GlaxoSmithKline (R.G.), Uxbridge, Middlesex, UK; GlaxoSmithKline (F.D.), Research Triangle Park; GlaxoSmithKline (S.S.), Raleigh, NC; Charles University (E.H.), Prague, Czech Republic; School of Medicine University of Belgrade (J.D.), Serbia; and San Raffaele Scientific Institute and Vita-Salute San Raffaele University (M.F.), Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000000125DOI Listing
February 2014

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

Clin Neurol Neurosurg 2013 Dec;115 Suppl 1:S42-8

Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, USA; Department of Neurology and Center of Clinical Neuroscience Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2013.09.020DOI Listing
December 2013